Peter Ellis, MD, MPH
Cards
About
Research
Publications
2025
Cost Disparities with Age in the Treatment of Advanced Non-Small-Cell Lung Cancer (NSCLC) in Ontario, Canada
Wang Y, Pond G, Gafni A, Kong C, Ellis P. Cost Disparities with Age in the Treatment of Advanced Non-Small-Cell Lung Cancer (NSCLC) in Ontario, Canada. Current Oncology 2025, 32: 346. PMID: 40558289, PMCID: PMC12191781, DOI: 10.3390/curroncol32060346.Peer-Reviewed Original ResearchConceptsCancer-attributable costsPhase of careNon-small-cell lung cancerAdvanced non-small-cell lung cancerInstitute for Clinical Evaluative SciencesHealthcare costsEnd-of-lifePre-diagnosis costsCost disparityEnd-of-life phaseDiagnosis of advanced non-small-cell lung cancerStage IV non-small-cell lung cancerTreatment of advanced non-small-cell lung cancerIV non-small-cell lung cancerRetrospective cohort studyLung cancerEvaluative SciencesPre-DiagnosisCancer diagnosisCohort studyOlder patientsDeceased patientsCareReceiving chemotherapyMedian agePerioperative toripalimab and chemotherapy in resectable non-small cell lung cancer: another weapon in the armamentarium
Coschi C, Ellis P. Perioperative toripalimab and chemotherapy in resectable non-small cell lung cancer: another weapon in the armamentarium. Journal Of Thoracic Disease 2025, 17: 3472-3477. PMID: 40529735, PMCID: PMC12170031, DOI: 10.21037/jtd-2025-91.Peer-Reviewed Original ResearchUse of broad-spectrum antibiotics in adult cancer patients presenting to emergency department with non-neutropenic fever and/or suspected infection
Li Y, Al Maqrashi Z, Zhan L, Siddiqui Z, Jin E, Ellis P. Use of broad-spectrum antibiotics in adult cancer patients presenting to emergency department with non-neutropenic fever and/or suspected infection. Supportive Care In Cancer 2025, 33: 383. PMID: 40237926, DOI: 10.1007/s00520-025-09419-4.Peer-Reviewed Original ResearchConceptsNon-neutropenic feverBroad-spectrum antibioticsBroad-spectrum intravenous antibioticsBroad-spectrum antibiotic useCancer patientsSuspected infectionAdult cancer patientsAntibiotic useIntravenous antibioticsEmergency departmentAntibiotics prescribed to patientsMethodsA retrospective cohort studySingle-center studyProportion of patientsRetrospective cohort studyStage IV cancerMultivariate logistic regressionImprove antibiotic stewardshipSystemic treatmentSolid malignanciesGenitourinary cancersAdult patientsAntibiotic stewardshipIV cancerCohort studySystematic Review for the Follow-up of Curatively Treated Patients With Lung Cancer
Shargall Y, Vella E, Del Giudice M, Dennie C, Ellis P, Kulkarni S, MacRae R, Ung Y. Systematic Review for the Follow-up of Curatively Treated Patients With Lung Cancer. Clinical Lung Cancer 2025, 26: e327-e341. PMID: 40240202, DOI: 10.1016/j.cllc.2025.03.003.Peer-Reviewed Original ResearchConceptsSmoking cessation interventionsPatient-reported outcome toolsPatient-reported outcomesRandomized Controlled TrialsCessation interventionsSystematic reviewOntario Health (Cancer Care OntarioNurse-led interventionRisk factorsClinical practice guidelinesQuality of lifeExercise trainingFollow-upManagement of signsCurative-intent treatmentPractice guidelinesControlled TrialsTarget populationCochrane LibraryFollow-up strategiesInterventionLung cancerSymptoms of recurrencePatient populationFollow-up of patients
2024
Update on Practical Management of Early-Stage Non-Small Cell Lung Cancer (NSCLC): A Report from the Ontario Forum
Cheema P, Wheatley-Price P, Cecchini M, Ellis P, Louie A, Moore S, Sheffield B, Spicer J, Villeneuve P, Leighl N. Update on Practical Management of Early-Stage Non-Small Cell Lung Cancer (NSCLC): A Report from the Ontario Forum. Current Oncology 2024, 31: 6979-6999. PMID: 39590145, PMCID: PMC11592966, DOI: 10.3390/curroncol31110514.Peer-Reviewed Original ResearchNon-small cell lung cancerEarly-stage non-small cell lung cancerImmune checkpoint inhibitorsCell lung cancerLung cancerManagement of early-stage non-small cell lung cancerPre-meeting surveyTreatment approachesReview practice patternsAdjuvant settingCheckpoint inhibitorsRadiation therapyOntario cancer centersTargeted therapySurgical considerationsTreatment algorithmReview recent dataClinical dataBiomarker testingCancer CenterTherapeutic strategiesPractice patternsCancerTherapyPatientsGrowth differentiation factor 15 (GDF15) predicts relapse free and overall survival in unresected locally advanced non-small cell lung cancer treated with chemoradiotherapy
Di Pastena F, Pond G, Tsakiridis E, Gouveia A, Ahmadi E, Biziotis O, Ali A, Swaminath A, Okawara G, Ellis P, Abdulkarim B, Ahmed N, Robinson A, Roa W, Valdes M, Kavsak P, Wierzbicki M, Wright J, Steinberg G, Tsakiridis T. Growth differentiation factor 15 (GDF15) predicts relapse free and overall survival in unresected locally advanced non-small cell lung cancer treated with chemoradiotherapy. Radiation Oncology 2024, 19: 155. PMID: 39511611, PMCID: PMC11542377, DOI: 10.1186/s13014-024-02546-y.Peer-Reviewed Original ResearchConceptsLocally advanced non-small cell lung cancerAdvanced non-small cell lung cancerNon-small cell lung cancerCell lung cancerOverall survivalDifferentiation factor 15GDF15 levelsLA-NSCLCTumor volumeSurvival outcomesUnresectable locally advanced non-small cell lung cancerLung cancerPhase II randomized clinical trialConcurrent chest radiotherapyIncreased GDF15 levelsUnresectable LA-NSCLCTreated with chemoradiotherapyGross target volumeGrowth differentiation factor 15Platinum-based chemotherapyPlasma GDF15 levelsRandomized to treatmentLevels of GDF15Patient blood plasmaRandomized clinical trialsCardiovascular Considerations During Cancer Therapy Gaps in Evidence and JACC: CardioOncology Expert Panel Recommendations
Leong D, Waliany S, Abdel-Qadir H, Atkins K, Neilan T, Lang N, Liu J, Blaes A, Mian H, Moore H, Hajjar L, Morgans A, Ellis P, Dent S. Cardiovascular Considerations During Cancer Therapy Gaps in Evidence and JACC: CardioOncology Expert Panel Recommendations. JACC CardioOncology 2024, 6: 815-834. PMID: 39801647, PMCID: PMC11711816, DOI: 10.1016/j.jaccao.2024.06.005.Peer-Reviewed Original ResearchCardiovascular toxicityCancer therapyContinuation of cancer therapySpectrum of toxicityDiverse health care professionalsExpert panelSevere cardiovascular diseaseHealth care professionalsExpert panel recommendationsCardiovascular ConsiderationsCardio-OncologyInvasive managementTherapy gapAdvanced cancerPrimary preventionTherapyCancerCardiovascular diseaseCardiovascular treatmentCare professionalsCardiovascular carePanel recommendationsPatientsToxicityTreatmentImplementation of Liquid Biopsy in Non-Small-Cell Lung Cancer: An Ontario Perspective
Breadner D, Hwang D, Husereau D, Cheema P, Doucette S, Ellis P, Kassam S, Leighl N, Maziak D, Selvarajah S, Sheffield B, Juergens R. Implementation of Liquid Biopsy in Non-Small-Cell Lung Cancer: An Ontario Perspective. Current Oncology 2024, 31: 6017-6031. PMID: 39451753, PMCID: PMC11505603, DOI: 10.3390/curroncol31100449.Peer-Reviewed Original ResearchNon-small-cell lung cancerAdvanced non-small-cell lung cancerCirculating tumor DNALung cancerMolecular profilingLiquid biopsyImplementation of liquid biopsiesComprehensive molecular profilingNon-small-cellHigh-risk patientsCancer-related deathsMinimally invasive methodTissue biopsy samplesTumor DNAInsufficient tissueMultidisciplinary working groupTherapy selectionTissue biopsiesBiomarker testingBiopsy samplesBiopsyGold standardInvasive methodEligibility criteriaCancerBiopsychosocial Associates of Psychological Distress and Post-Traumatic Growth among Canadian Cancer Patients during the COVID-19 Pandemic
Zhang K, Mukherjee S, Pond G, Roque M, Meyer R, Sussman J, Ellis P, Bryant-Lukosius D. Biopsychosocial Associates of Psychological Distress and Post-Traumatic Growth among Canadian Cancer Patients during the COVID-19 Pandemic. Current Oncology 2024, 31: 5354-5366. PMID: 39330023, PMCID: PMC11431811, DOI: 10.3390/curroncol31090395.Peer-Reviewed Original ResearchConceptsPost-traumatic growthCanadian cancer patientsPsychological distressAssociation of psychological distressAssociated with psychological distressLevels of psychological distressModerate to severe levelsPsychological patient outcomesFear of recurrenceAssociated with levels of distressCancer patientsSevere psychological distressCross-sectional surveyLevels of distressDisease-related informationRegional Cancer CentrePatient health recordsSelf-report questionnairesCOVID-19 pandemicSafety behaviorCancer careIllness perceptionsHealth recordsNegative psychological outcomesOngoing care
2023
Molecular Testing in Non–Small-Cell Lung Cancer: A Call to Action
Sathiyapalan A, Ellis P. Molecular Testing in Non–Small-Cell Lung Cancer: A Call to Action. JCO Oncology Practice 2023, 20: 7-9. PMID: 38033274, DOI: 10.1200/op.23.00669.Peer-Reviewed Original Research
Academic Achievements & Community Involvement
Clinical Care
Overview
Peter J. Ellis, MD, provides primary care to adult patients, including preventive care and management of acute and chronic illnesses. “I am inspired by my patients who have serious medical issues that they bravely address,” says Dr. Ellis. “As privileged witness to their life stories, I try to share their valuable perspectives and lessons they have learned with other patients facing similar challenges.”
Dr. Ellis specializes in managing complex medical problems, including psychosocial needs, for his patients. He is president of the board of directors for Project Access New Haven, a nonprofit organization that offers free medical care to uninsured residents with urgent medical needs. The program, which Dr. Ellis helped create in New Haven after launching Project Access in Waterbury in 2004, brings together more than 300 physician volunteers and hooks patients up with navigators who can help identify and remove barriers to care.
“At Yale we have lots of medical resources and specialists at our disposal. My job is both to provide direct care and to guide and coordinate care provided by specialists,” Dr. Ellis says. “I am excited by the prospect of developing a patient-centered medical home that encourages patients to communicate more often and engage in healthy behaviors outside the traditional annual office visit.”
Clinical Specialties
Yale Medicine News
News & Links
News
- June 02, 2025
Primary Care & Psychiatry Clerkship Honors Excellent Community Physician Teachers
- February 18, 2025
Voluntary Faculty Awards Honor Outstanding Educators
- January 06, 2025
New Professors in the Department of Internal Medicine
- February 14, 2024
Yale Faculty Honored at Inaugural Voluntary Faculty Awards
Get In Touch
Contacts
General Internal Medicine
PO Box 208056, 333 Cedar Street
New Haven, CT 06520-8056
United States
Locations
Patient Care Locations
Are You a Patient? View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.